Lipocine (NASDAQ:LPCN – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Lipocine to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, risk and earnings.
Analyst Ratings
This is a summary of current ratings for Lipocine and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipocine | 1 | 1 | 1 | 0 | 2.00 |
| Lipocine Competitors | 7845 | 13798 | 25820 | 1039 | 2.41 |
Lipocine presently has a consensus price target of $4.00, indicating a potential upside of 140.96%. As a group, “Pharmaceuticals” companies have a potential upside of 24.58%. Given Lipocine’s higher probable upside, equities research analysts clearly believe Lipocine is more favorable than its peers.
Institutional and Insider Ownership
9.1% of Lipocine shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.7% of Lipocine shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Lipocine and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipocine | -249.23% | -46.52% | -41.75% |
| Lipocine Competitors | -2,400.61% | -215.91% | -15.58% |
Valuation & Earnings
This table compares Lipocine and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lipocine | $1.98 million | -$9.63 million | -1.30 |
| Lipocine Competitors | $3.55 billion | $3.17 billion | 559.01 |
Lipocine’s peers have higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Lipocine has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Lipocine’s peers have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.
Summary
Lipocine peers beat Lipocine on 8 of the 12 factors compared.
About Lipocine
Lipocine Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral treatments for health conditions with significant unmet medical needs. Its proprietary drug-delivery technology is designed to enable medicines that may otherwise require different formulations or routes of administration to be taken orally. The company’s lead commercial-stage product is Tlando, an oral testosterone-replacement therapy approved in the United States for adult men with testosterone deficiency.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
